Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Chip stocks, megacaps steer S&P 500, Nasdaq to record highs



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Chip stocks, megacaps steer S&P 500, Nasdaq to record highs</title></head><body>

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.

S&P 500 notches 35th record closing high this year

Lilly up after data shows Mounjaro more efficient than Wegovy

Indexes: Dow down 0.38%, S&P up 0.21%, Nasdaq up 0.47%

Updated at 10:05 a.m. ET

By Lisa Pauline Mattackal and Ankika Biswas

July 9 (Reuters) - The S&P 500 and the Nasdaq hit record highs on Tuesday, powered by semiconductors andmegacaps, as Congress heard testimony from Federal Reserve Chair Jerome Powell, who said more "good" economic data would strengthen the case for interest-rate cuts.

AI-chip favorite Nvidia NVDA.O jumped 4%, while Applied Materials AMAT.O and Micron Technology MU.O gained 2% and 3%, respectively, steering the Philadelphia SE Semiconductor index .SOX to a record high.

The S&P 500 Information Technology Index .SPLRCT also hit an all-time high, along with megacaps including Alphabet GOOGL.O and Apple AAPL.O, while Meta Platforms META.O and Amazon.com AMZN.O rose0.9% and 0.3%, respectively.

Monday markedthe 35th instance of the S&P 500setting a fresh closing record this year, as sharp gains in AI-linked and other tech shares kept equity sentiment bright, offsetting the uncertainty around the Fed'srate-cut path.

However, the Dow Jones .DJI underperformed, with a 2% fall in Salesforce CRM.N being the biggest drag on the blue-chip index.

Meanwhile, in his Congressional testimony, Powell said that while inflation "remains above" the 2% soft-landing target, it has been improving in recent months and "more good data would strengthen" the case for rate cuts.

"It does sound like Powell is just looking for a few more months of decent inflation data in order to have the confidence to start cutting, so that could put a September rate cut in play," said Brian Jacobsen, chief economist at Annex Wealth Management.

The last set of economicprojections from the central bank's policymakers showed anexpectation of just one rate cut this year. But markets have stuck to pricing in 50 basis points of easing, seeing a nearly 72% chance for a 25 bps cut at the Fed's September meeting, according to CME's FedWatch.

Those bets were at under50% a month ago.

Crucial inflation data is also due this week, including Thursday'sconsumer price index and the producerprice index reading on Friday.

Investors also awaitthe start of the second-quarter corporate earnings season this week, with big banks due to report on Friday.

Analysts, on average, see S&P 500 companies increasing their aggregate earnings per share by 10.1% in the second quarter, up from an 8.2% increase in the first quarter, according to LSEG I/B/E/S data.

At 10:05 a.m. ET, the Dow Jones Industrial Average .DJI was down 147.89 points, or 0.38%, at 39,196.90, the S&P 500 .SPX was up 11.96 points, or 0.21%, at 5,584.81, and the Nasdaq Composite .IXIC was up 86.31 points, or 0.47%, at 18,490.05.

Among single movers, Tempus AI TEM.O jumped7.5% after multiple brokerages including J.P.Morgan and Morgan Stanley initiated coverage of the stock with bullish ratings.

Eli Lilly <LLY.N> edgedup 0.6% aftera data analysis report showed its treatment Mounjaro leads to faster and greater weight loss than Novo Nordisk's obesity drug, Wegovy.

CVS Health CVS.N and UnitedHealth Group UNH.N fell0.9% and 0.4%, respectively, after the U.S. Federal Trade Commission said a handful of pharmacy benefit managersexercized an outsized influence over prescription drug prices.

Declining issues outnumbered advancers for a 1.51-to-1 ratio on the NYSE, andfor a 1.31-to-1 ratio on the Nasdaq.

The S&P index recorded 19 new 52-week highs and ninenew lows, while the Nasdaq recorded 38 new highs and 74 new lows.



Reporting by Lisa Mattackal and Ankika Biswas in Bengaluru; Editing by Pooja Desai

</body></html>

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.